Compass Pathways (NASDAQ: CMPS) Stock Surges on Positive Analyst Outlook and Strong Psilocybin Therapy Trial Results

• Analyst Stifel Nicolaus raised its price target for Compass Pathways (NASDAQ: CMPS), indicating strong confidence in the company's future prospects.
• The positive outlook follows robust long-term data from the COMP006 Phase 3 clinical trial for its COMP360 psilocybin therapy, targeting treatment-resistant depression (TRD).
• Consistent positive results across multiple Phase 3 trials reinforce the therapy's effectiveness and safety, supporting a projected launch in 2027 and boosting investor confidence.

Compass Pathways (NASDAQ: CMPS) is a mental health care company developing new therapies for difficult-to-treat conditions. It focuses on its COMP360 psilocybin therapy for treatment-resistant depression (TRD). This is a condition where patients do not respond to standard depression treatments. The company has a market capitalization of approximately $1.25 billion.

On July 7, 2026, analyst Paul Matteis of Stifel Nicolaus raises the price target for Compass Pathways to $21.00. As highlighted by StreetInsider, the stock's price is $12.99 when the target is set. This new analyst price target represents a potential increase of about 61.66%, showing analyst confidence in the company's direction and its potential for future stock performance.

This positive analyst outlook follows the company's announcement of long-term data from its second Phase 3 clinical trial. The trial, known as COMP006, evaluates the effectiveness of its COMP360 psilocybin treatment. The study focuses specifically on patients with treatment-resistant depression, a key area for the mental health care company.

As reported by Benzinga, the 26-week results from the study of nearly 600 patients show strong performance. The data shows that 39% of patients who receive two 25mg doses of COMP360 achieve a significant reduction in their depression scores. These positive effects are maintained through at least Week 26, highlighting the durable response of the psilocybin therapy.

These findings are consistent with a previous Phase 3 trial, COMP005, which strengthens the case for the treatment's effectiveness. According to Businesswire, the clinical trial results support a durable response with a well-tolerated safety profile. This allows Compass Pathways to maintain its projected launch timeline of 2027 for the therapy, further boosting investor confidence in the company's pipeline.